Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GSK delivers continued strong performance
Q2 2025 performance highlights
Download (PDF - 1.1MB)GSK highlights new findings on Dementia and Alzheimer’s Disease at AAIC 2025, building on leadership in immunology and inflammation
Real-world data shows an association between Recombinant Zoster Vaccine (RZV) and potential reduced risk of dementia.
Download (PDF - 228.2KB)GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD
Download (PDF - 167.6KB)Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma
Sixth regulatory approval for Blenrep combinations with applications under review in all major markets
Download (PDF - 244.0KB)GSK announces extension of US Food and Drug Administration review period for Blenrep (belantamab mafodotin-blmf) in relapsed/refractory multiple myeloma
New PDUFA date scheduled for 23 October 2025.
Download (PDF - 231.9KB)GSK provides update on US FDA advisory committee review of Blenrep (belantamab mafodotin-blmf) combinations for patients with relapsed/refractory multiple myeloma
The US FDA Oncologic Drugs Advisory Committee voted against the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations.
Download (PDF - 221.8KB)US FDA approves GSK’s Shingrix in a prefilled syringe presentation
Prefilled syringe presentation offers a convenient administration option to healthcare professionals
Download (PDF - 228.3KB)ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment
Agreement allows manufacturers to develop, manufacture and supply generic LA injectable cabotegravir for treatment in 133 countries.
Download (PDF - 230.1KB)ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
Multiple real-world studies show consistent high effectiveness of Vocabria + Rekambys across a broad range of populations.
Download (PDF - 341.3KB)US FDA accepts application to review expanded use of GSK’s RSV vaccine, Arexvy, for adults 18-49 at increased risk
More than 21 million US adults under the age of 50 have at least one risk factor for severe RSV infection
Download (PDF - 182.6KB)ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025
Real-world and implementation data describe effectiveness of long-acting Vocabria + Rekambys (CAB+RPV LA) for HIV treatment.
Download (PDF - 304.2KB)GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
GSK plc today announced the completion of its previously announced acquisition of efimosfermin alfa from Boston Pharmaceuticals
Download (PDF - 151.5KB)Price of world’s first malaria vaccine (RTS,S) for children in endemic countries to be reduced by more than half, to less than $5
Price reduction is commitment by Bharat Biotech made possible through partnership with GSK.
Download (PDF - 186.0KB)Linerixibat accepted for review by the European Medicines Agency for cholestatic pruritus in patients with primary biliary cholangitis (PBC)
Submission based on data from positive GLISTEN phase III trial
Download (PDF - 163.2KB)Japan’s Ministry of Health, Labour and Welfare accepts regulatory application to expand use of GSK’s RSV vaccine, Arexvy, in adults aged 18-49 at increased risk of severe RSV disease
If approved, GSK’s RSV vaccine would be the first available in Japan to help protect this group
Download (PDF - 232.0KB)GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older
Regulatory decision anticipated H1 2026.
Download (PDF - 191.1KB)GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development
GSK plc announced today that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech International Limited.
Download (PDF - 196.8KB)Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)
Application based on data from positive GLISTEN phase III trial
Download (PDF - 155.6KB)GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio
GSK today announced that data across the oncology pipeline and portfolio will be presented at ASCO and EHA.
Download (PDF - 350.5KB)PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee
Data to be part of a planned US FDA filing in H2 2025
Download (PDF - 134.4KB)